

NOV 17 2004

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being transmitted via facsimile number (703) 872-9306 to Commissioner for Patents, United States Patent and Trademark Office, on the date shown below:

By: Barbara Bryant Date: November 17, 2004
Barbara Bryant

Patent
Attorney's Docket No. P-154-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
)	
MORAN et al.)	Group Art Unit: 1621
)	
Application No.: 10/627,555)	Examiner: Shailendra Kumar
)	
Filed: July 25, 2003)	
)	
For: CRYSTALLINE β_2 ADRENERGIC)	
RECEPTOR AGONIST)	
)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants respectfully submit this Information Disclosure Statement (IDS) in conformance with 37 C.F.R. §§1.97 and 1.98 for the above-identified patent application. The document being submitted for consideration by the Examiner is listed on the enclosed Form PTO/SB/08a.

The filing of this IDS shall not be construed as a representation that a search has been made (37 C.F.R. §1.97(g)), nor as an admission that the information submitted herewith is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)) of the subject application.

Pursuant to 37 C.F.R. §1.98(a)(2)(ii), the copy of the U.S. patent cited on the accompanying PTO Form PTO/SB/08a is not being submitted.

Attorney Docket No. P-154-US1
Application Serial No.: 10/627,555

Page 1 of 2

Applicants respectfully request that the Examiner consider the document cited on the accompanying PTO Form PTO/SB/08a. After such consideration, the Examiner is respectfully requested to return an initialed copy of the enclosed form PTO/SB/08a to Applicants with the next Office Action on the merits.

This IDS is being filed before the mailing date of a first Office Action on the merits for this application and therefore, no fee or certification is required under 37 C.F.R. §1.97(b). In the event that an Office Action is mailed prior to receipt of this paper, the Commissioner is hereby authorized to charge any requisite fees for submission of this paper to Deposit Account No. 50-0344.

Any questions regarding this IDS should be directed to undersigned agent for Applicants at (650) 808-3764 (direct).

Respectfully submitted,

THERAVANCE, INC.

Date: November 17, 2004

By: Roberta P. Saxon
Roberta P. Saxon, Ph.D.
Registration No. 43,087

THERAVANCE, INC.
901 Gateway Boulevard
South San Francisco, CA 94080
Tel: (650) 808-6000
Fax: (650) 808-6078

